Article

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

2025-09-01

Abstract excerpt

<title>Abstract</title> <p>The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib in 63 participants with metastatic pancreatic cancer with disease control on platinum-based chemotherapy. Participants were prospectively stratified into three cohorts by type of HRD: Cohort A (homologous recombination deficient [HRD] by BRCA1/2 or PALB2 mutations, N=33), Cohort B (non-core HRD mutations, N=15), a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49d70301-a001-5c92-8f23-b0f40b0419ea
DOI: 10.21203/rs.3.rs-7334701/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialDOI 10.21203/rs.3.rs-7334701/v1Read

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Semantic proximity Read

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studySemantic proximity Read

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.Semantic proximity Read

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.Semantic proximity Read

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.Semantic proximity Read

Targeting DNA Damage Response and Replication Stress in Pancreatic CancerSemantic proximity Read

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor ProgramSemantic proximity Read

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomesSemantic proximity Read

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerSemantic proximity Read

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT databaseSemantic proximity Read

Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancerSemantic proximity Read